Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a China-based company mainly engages in the research and development, production and sales of drugs. The Company is mainly engaged in the research and development, manufacturing and commercialization of innovative drugs in oncology, immunology and other therapeutic fields. The Company's products are antibody-drug conjugates (ADCs) SKB264 and A166. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.

Employees

1,870

Sector

Biotechnology & Medical Research

Calendar

03-30 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
11/02/26	438.00 $	+0.18%	483,846
10/02/26	437.20 $	+4.29%	571,684
09/02/26	419.20 $	-0.95%	287,984
06/02/26	423.20 $	+0.71%	354,009
05/02/26	420.20 $	-0.61%	449,348

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

438.00HKD

Average target price

535.40HKD

Spread / Average Target

+22.24%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 11:08:13 11/02/2026 +03			5-day change	1st Jan Change
438.00 ^HKD	+0.18%		+9.06%	+11.68%

02-06	Sichuan Kelun-Biotech biopharmaceutical says Trop2 adc sacituzumab tirumotecan approved for marketing for fourth indication by China's NMPA	RE
02-06	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Fourth Indication for Sacituzumab Tirumotecan (Sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer	CI

Capitalization	90.29B 102B 13.06B 11.01B 10.08B 9.57B 17.75B 1,185B 18.35B 116B 46.39B 570B 48.99B 47.98B 2,002B	P/E ratio 2025 *	-182x	P/E ratio 2026 *	-35,523x
Enterprise value	87.36B 98.79B 12.64B 10.65B 9.75B 9.26B 17.17B 1,147B 17.75B 112B 44.88B 551B 47.4B 46.42B 1,937B	EV / Sales 2025 *	44.7x	EV / Sales 2026 *	28.6x
Free-Float	59.59%	Yield 2025 *	-	Yield 2026 *	-

02-06	Sichuan Kelun-Biotech biopharmaceutical says Trop2 adc sacituzumab tirumotecan approved for marketing for fourth indication by China's NMPA	RE
02-06	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Fourth Indication for Sacituzumab Tirumotecan (Sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer	CI
02-06	Sichuan Kelun-Biotech Secures China Approval for New Breast Cancer Drug Indication	MT
01-19	Sichuan Kelun-Biotech Renews R&D Procurement Deal With China Resources Kelun; Shares Slip 5%	MT
01-07	Sichuan Kelun-Biotech Biopharmaceutical says subscription for BOC structured deposit II terminated	RE
01-07	Sichuan Kelun-Biotech Subscribes to Wealth Management Products	MT
01-06	Sichuan Kelun-Biotech Biopharmaceutical subscribes for wealth management products	RE
01-05	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Breakthrough Therapy Designation for First-Line Treatment of PD-L1 Positive NSCLC by the National Medical Products Administration	CI
01-05	Sichuan Kelun-Biotech Receives Chinese Regulatory Nod to Begin Human Trials of SKB105	MT
01-05	Sichuan Kelun-Biotech Biopharmaceutical SAC-TMT in combination with immunotherapy pembrolizumab granted breakthrough therapy designation by NMPA	RE
01-05	Sichuan Kelun-Biotech Lung Cancer Treatment Granted Breakthrough Therapy Designation in China	MT
01-04	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Investigational New Drug Application for Skb105	CI
12-31	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Sales and Distribution Framework Agreement	CI

20/10/25	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO	CI
20/08/25	Nomura Downgrades Sichuan Kelun-Biotech Biopharmaceutical to Neutral From Buy, Adjusts Price Target to HK$434.36 From HK$211.87	MT
20/08/25	Jefferies Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$520 from HK$300, Keeps at Buy	MT
26/03/25	Jefferies Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$300 from HK$240, Keeps at Buy	MT
18/02/25	Nomura Adjusts Sichuan Kelun-Biotech Biopharmaceutical's Price Target to HK$211.87 From HK$195.51, Keeps at Buy	MT

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Stock

Equities

6990

CNE1000062J1

Biotechnology & Medical Research

Valuation: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Chart: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Latest news: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Analysts' recommendations: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Press Releases: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

01-15	Kelun-Biotech Showcases Innovative Achievements and Future Development Strategy at the 44th Annual JPM Healthcare Conference	PR
18/08/25	KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS	PR
26/03/25	ANNOUNCEMENT OF ANNUAL RESULTS FOR 2024	PR
11/01/25	Kelun-Biotech Announce Exclusive License Agreement For SKB378/HBM9378, an Anti-thymic Stromal Lymphopoietin (TSLP) Monoclonal Antibody (mAb).	PR

1 day	+0.18%
1 week	+9.06%
Current month	+5.44%
1 month	-8.06%
3 months	+5.95%
6 months	+8.68%
Current year	+11.68%

1 week	410	452.8
1 month	393.4	495
Current year	389.4	495
1 year	171.1	581
3 years	60.6	581
5 years	60.6	581
10 years	60.6	581

Manager	Title	Age	Since
Jun You Ge CEO	Chief Executive Officer	54	01/03/2022
Ze Jian Zhou DFI	Director of Finance/CFO	43	17/08/2022
Xiao Ping Jin CTO	Chief Tech/Sci/R&D Officer	49	06/09/2021

Director	Title	Age	Since
Ge Xin Liu CHM	Chairman	75	01/03/2022
Jun You Ge BRD	Director/Board Member	54	25/02/2022
Si Chuan Liu BRD	Director/Board Member	42	22/11/2016

	2025 *	2026 *
Net sales	1.95B 2.21B 282M 238M 218M 207M 384M 25.62B 397M 2.51B 1B 12.32B 1.06B 1.04B 43.29B	3.04B 3.44B 440M 371M 340M 323M 598M 39.96B 619M 3.92B 1.56B 19.21B 1.65B 1.62B 67.5B
Net income	-541M -612M -78.3M -65.99M -60.4M -57.39M -106M -7.11B -110M -697M -278M -3.42B -294M -288M -12B	-14.94M -16.89M -2.16M -1.82M -1.67M -1.58M -2.94M -196M -3.04M -19.22M -7.67M -94.28M -8.1M -7.94M -331M
Net Debt	-2.93B -3.31B -424M -357M -327M -311M -576M -38.46B -595M -3.77B -1.51B -18.49B -1.59B -1.56B -64.98B	-3.3B -3.73B -477M -402M -368M -350M -648M -43.3B -670M -4.24B -1.69B -20.82B -1.79B -1.75B -73.15B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.18%	+9.06%	+141.59%	-	13.04B
ARGENX SE	-1.16%	-2.34%	+13.14%	+100.74%	51.64B
WUXI APPTEC CO., LTD.	+0.78%	+7.97%	+74.30%	+13.78%	43.87B
INSMED INCORPORATED	-1.19%	-3.58%	+83.99%	+641.25%	31.68B
BIONTECH SE	-0.18%	+0.43%	-4.59%	-23.61%	27.33B
WUXI BIOLOGICS (CAYMAN) INC.	+3.45%	+11.95%	+89.91%	-35.86%	21.18B
GENMAB A/S	-2.92%	-6.25%	+37.09%	-30.90%	19.02B
AKESO, INC.	-0.47%	+4.26%	+62.97%	+136.40%	12.45B
EXELIXIS, INC.	-0.73%	+0.04%	+30.04%	+141.18%	11.57B
SUMMIT THERAPEUTICS INC.	-0.10%	+7.21%	-18.97%	+646.86%	11.76B
Average	-0.21%	+1.87%	+50.95%	+176.65%	24.35B
Weighted average by Cap.	-0.25%	+1.11%	+48.61%	+152.14%